StreetInsider.com News Articles

Barclays Double Downgrades Cellectis (CLLS) to Underweight

Wed, 16 Sep 2026 03:49:37 -0400

Barclays analyst Lukas Shumway downgraded Cellectis (NASDAQ: CLLS) from Overweight to Underweight with a price target of $1.30 (from $9.00).

The analyst comments: “We downgrade CLLS to Underweight (from Overweight) due to a lack of conviction in the company's new gene editing programs, .HEAL-101 in severe hypertriglyceridemia (sHTG) and .HEAL-201 in hypercholesterolemia. We ascribe negative per-share NPVs to the new programs, -$4 to .HEAL-101 and -$2 to .HEAL-201. We've also reduced lasme-cel (-$1 from $0) and removed eti-cel ($0 from $4) and Pipeline ($0 from $1) values from our models, with some R&D spend allocated as the company finishes the ongoing

Barclays Double Downgrades Cellectis (CLLS) to Underweight

Wed, 16 Sep 2026 03:49:37 -0400

Barclays analyst Lukas Shumway downgraded Cellectis (NASDAQ: CLLS) from Overweight to Underweight with a price target of $1.30 (from $9.00).

Cellectis (CLLS) PT Lowered to $3 at Wells Fargo

Tue, 15 Sep 2026 06:34:12 -0400

Wells Fargo analyst Yanan Zhu lowered the price target on Cellectis (NASDAQ: CLLS) to $3.00 (from $4.00) while maintaining a Equal Weight rating.

Citizens Downgrades Cellectis (CLLS) to Market Perform

Tue, 15 Sep 2026 03:16:47 -0400

Citizens analyst Silvan Tuerkcan downgraded Cellectis (NASDAQ: CLLS) from Market Outperform to Market Perform.

The analyst comments: “Cellectis announced a major change to its strategy, halting further development of allogeneic CAR T cells for hematology and pivoting to TALEN-based, in vivo, genetic medicines for the treatment of cardiovascular disease (CVD). Importantly, CLLS' multiple partnerships (details below) remain unaffected, and the company projects an extended runway into 2028 with its renewed focus on genetic medicines. While we are bullish on genetic medicines for CVD, and believe CLLS may provide a unique approach, subsequent clinical catalysts have been pushed back to late-2027/2028, and

Citizens Downgrades Cellectis (CLLS) to Market Perform

Tue, 15 Sep 2026 03:16:47 -0400

Citizens analyst Silvan Tuerkcan downgraded Cellectis (NASDAQ: CLLS) from Market Outperform to Market Perform.

Cellectis (CLLS) PT Lowered to $8 at Baird

Mon, 14 Sep 2026 08:58:50 -0400

Baird analyst Madhu Kumar lowered the price target on Cellectis (NASDAQ: CLLS) to $8.00 (from $10.00) while maintaining a Outperform rating.

Cellectis (CLLS) Tops Q2 EPS by 4c

Thu, 06 Aug 2026 17:53:39 -0400

Cellectis (NASDAQ: CLLS) reported Q2 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $6.9 million versus the consensus estimate of $10.97 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

Prolynx, a biotechnology company developing ultra-long-acting medicines for obesity and metabolic diseases, has appointed Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer, according to a company statement.

Harnest brings experience in life sciences finance, including involvement in three Nasdaq IPOs and more than $1 billion in capital raised. He most recently served as CFO of Totus Medicines and previously held senior roles at Metagenomi (Nasdaq: MGX) and Cellectis (Nasdaq: CLLS).

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx names CFO and CSO to advance obesity drug portfolio

Wed, 15 Jul 2026 08:01:18 -0400

"Prolynx is building in one of the most important and dynamic areas of medicine, in a field still largely defined by weekly injectable therapies," Harnest said.

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

Wed, 15 Jul 2026 08:00:00 -0400

EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer. The appointments deepen the company’s leadership bench as Prolynx advances multiple ultra-long-acting candidates for obesity and related metabolic diseases toward IND-enabling studies.